Rectal Cancer: Updates in Staging and Treatment

PRESENTED BY
The Digestive Disease Institute at Virginia Mason

Friday, February 9, 2018
Seattle
Faculty

**COURSE DIRECTORS**

**Hagen F. Kennecke, MD, MHA, FRCPC**  
Medical Director, Cancer Institute  
Virginia Mason, Seattle Wash.

**Anjali S. Kumar, MD, MPH, FACS, FASCRS**  
Director, Colon and Rectal Surgery Program  
Virginia Mason, Seattle Wash.

**Bruce S. Lin, MD**  
Hematologist-Oncologist  
Digestive Disease Institute at Virginia Mason, Seattle Wash.

**Otto Lin, MD, MSc, AGAF, FASGE, FACG**  
Deputy Section Head, Gastroenterology Section; Director, Quality Improvement  
Digestive Disease Institute at Virginia Mason, Seattle Wash.

**GUEST FACULTY**

**Carl J. Brown, MD, MSc, FACS, FRCSC**  
Head, Division of General Surgery; Providence Health Care Chair, Section of Colorectal Surgery; University of British Columbia Clinical Research Scientist, Centre for Health Evaluation and Outcomes Research, St. Paul’s Hospital, Vancouver, British Columbia

**Cathy Eng, MD, FACP**  
Sophie Caroline Steves Distinguished Professor in Cancer Research  
Associate Medical Director, Colorectal Center  
Director of Network Clinical Research, Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center, Houston, Texas

**Harvey J. Mamon, MD, PhD**  
Associate Professor, Radiation Oncology, Harvard Medical School  
Director of Gastrointestinal Radiation Oncology  
Brigham and Women’s Hospital / Dana Farber Cancer Institute, Boston, Mass.

**Elizabeth C. Wick, MD**  
Associate Professor of Surgery  
Center for Colorectal Surgery  
University of California San Francisco, San Francisco, Calif.

**VIRGINIA MASON FACULTY**

**Coleen M. Burton, BSN, RN**  
Colorectal Surgery

**David L. Coy, MD, PhD**  
Section Head, MRI, Radiology

**Felicia P. Cummings, MD**  
Radiologist

**Cheryl Davison, MD**  
Director, Radiation Oncology  
North Star Lodge Cancer Center

**Joanna K. Law, MD, MA (ed), FRCP(C)**  
Gastroenterologist  
Digestive Disease Institute

**Ravi Moonka, MD, FACS**  
Colorectal Surgeon  
Digestive Disease Institute

**Lesley Weinberg, PT, DPT, GCS**  
Board Certified Geriatric Clinical Specialist  
Physical Medicine and Rehabilitation
This course spans the staging and treatment of patients with rectal cancer, with a focus on new developments and controversies in staging, duration of chemotherapy, and a variety of surgical approaches.

Join colleagues from around the Pacific Northwest to learn about the risks and benefits of shorter duration of curative chemotherapy, a major new development in colorectal cancer. Differing staging techniques including controversies about optimal modalities with MRI and endo-rectal ultrasound will be discussed, as will surgical therapy — with concentration on which patients should be considered for minimally invasive and robotic surgery. Discover the important role of the microbiome and its relevance to treatment and prevention of GI malignancies. Review evidence-based surveillance practice and guidelines for patients who completed definitive therapy vs. patients who chose a “watch and wait” approach. Find out about clinical trials currently available to patients, and new radiation treatment strategies and their role. Teaching methods include lecture, Q&A with faculty, panel discussion and case presentation.

**TARGET AUDIENCE:**
This course is appropriate for oncologists, gastroenterologists, radiologists, internists and general and colorectal surgeons; advanced practice providers; GI, surgical and oncology fellows; residents; and GI and oncology nurses who wish to update their knowledge and become familiar with new information and advanced therapeutic approaches to rectal cancer.

**OBJECTIVES:**
At the conclusion of this activity, participants should be able to:

- Compare many emerging treatment options to the current standard of care for locally advanced rectal cancer
- Determine low versus high risk category patients for whom three months of chemotherapy may be adequate
- Describe different rectal cancer staging techniques
- Specify indications for pelvic MRI versus endorectal ultrasound for rectal cancer staging
- Review evidence for surveillance of patients with colorectal cancer
- Discuss multidisciplinary management of early rectal cancer cases
- Summarize the advantages of robotic surgery in general, and describe the advantages of robotic surgery that are specific to rectal surgery
- Discuss the role of clinical trials in the management of rectal cancer
- Describe the role of the microbiome and its relevance to treatment of GI malignancies
- Discuss roles and sequences of radiation, chemotherapy, and surgical resection
- Relate the complexities of post-operative care, including stoma care, incontinence, and anastomotic leak
- Describe surveillance protocols after complete clinical, radiographic and endoscopic response is achieved
### Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td>Registration opens, breakfast selection available</td>
</tr>
<tr>
<td>7:30 a.m.</td>
<td><strong>Grand Rounds Presentation: Duration of Therapy in Adjuvant Colorectal Cancer</strong></td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>8:45 a.m.</td>
<td><strong>Opening Remarks and Course Overview</strong></td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td><strong>Updates in Radiation Therapy</strong></td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td><strong>Debate: EUS vs. MRI in Determination of Rectal Cancer Stage</strong></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td><strong>Surgical Treatment of Early Rectal Cancer</strong></td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td><strong>Rectal Cancer Follow-up: How, What, When</strong></td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td><strong>Panel Discussion: Case Presentations – Early Rectal Cancer</strong></td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td><strong>Surgery for Locally Advanced Rectal Cancer: Modern Approaches to Total Mesorectal Excision</strong></td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td><strong>Rectal Cancer Trials and Novel Treatment Strategies</strong></td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Lunch (provided)</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td><strong>Influence of the Gut Microbiome on Colorectal Cancer</strong></td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td><strong>Panel Discussion: Case Presentations – Locally Advanced Rectal Cancer</strong></td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td><strong>Panel Discussion: Navigating Post-Surgical Dilemmas</strong></td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td><strong>Pros &amp; Cons of Non-operative Management (NOM)/Watch and Wait</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><strong>Closing Remarks</strong></td>
</tr>
<tr>
<td>3:45 p.m.</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
REGISTRATION:
Rectal Cancer: Updates in Staging and Treatment
Friday, February 9, 2018

Please print clearly

NAME ___________________________ DEGREE/CREDS

SPECIALTY ___________________________

ORGANIZATION ___________________________

ADDRESS ___________________________

CITY/STATE/ZIP ___________________________

PHONE ___________________________ E-MAIL ___________________________

Please provide one question for the faculty:

I will attend at the Videoconferencing Site in: ___________________________

For information, call (206) 341-0142.

Please add me to your e-mail list for news of upcoming CME courses at Virginia Mason.

PAYMENT:
Tuition: $195.00

☐ Check enclosed. Make check payable to VMMC – CME

☐ Please charge my: ☐ VISA  ☐ MasterCard  ☐ American Express  ☐ Discover

CARD NUMBER ___________________________ EXPIRATION DATE ___________________________

CARDHOLDER NAME ___________________________ SIGNATURE ___________________________